Research Analysts’ Upgrades for November, 15th (HLUYY, HQCL, HSGX, HTGM, HWCC, ILG, IMIAY, IOTS, IPCC, IPWR)

Research Analysts’ upgrades for Wednesday, November 15th:

H Lundbeck A/S (OTCMKTS:HLUYY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $62.00 price target on the stock. According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “

Hanwha Q CELLS Co. (NASDAQ:HQCL) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $9.50 price target on the stock. According to Zacks, “Hanwha Q CELLS Co., Ltd. is a photovoltaic manufacturer for solar cells and modules. The company offers the full spectrum of photovoltaic products, applications and solutions, from modules to kits to systems to large scale solar power plants. It operates primarily in Europe, North America, Asia, South America, Africa and the Middle East. Hanwha Q CELLS Co. Ltd., formerly known as Hanwha SolarOne Co. Ltd., is headquartered in Seoul, South Korea. “

Histogenics Corporation (NASDAQ:HSGX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $2.25 price target on the stock. According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “

HTG Molecular Diagnostics (NASDAQ:HTGM) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $2.50 target price on the stock. According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “

Houston Wire & Cable (NASDAQ:HWCC) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $7.00 price target on the stock. According to Zacks, “With more than three decades of experience in the electrical industry, HOUSTON WIRE & CABLE COMPANY is one of the largest distributors of specialty wire and cable and related services in the U.S. electrical distribution market. Headquartered in Houston, HWCC has sales and distribution facilities in Atlanta, Baton Rouge, Charlotte, Chicago, Denver, Houston, Los Angeles, Philadelphia, San Francisco, Seattle and Tampa. Standard stock items available for immediate delivery include continuous and interlocked armor, instrumentation, medium voltage, high temperature, portable cord, power cables and private branded products, including LifeGuard, a low-smoke, zero-halogen cable. HWCC’s comprehensive value-added services include same-day shipping, knowledgeable sales staff, inventory management programs, just-in-time delivery, logistics support, customized internet-based ordering capabilities and round-the-clock, throughout-the-year service. “

ILG (NASDAQ:ILG) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “ILG, Inc. offers owners, members and guests benefits and services, as well as destinations through its portfolio of resorts and clubs. The company’s operating businesses include Aqua-Aston Hospitality, Hyatt Vacation Ownership, Interval International, Trading Places International, Vacation Resorts International, VRI Europe and Vistana Signature Experiences. ILG, Inc., formerly known as Interval Leisure Group Inc., is headquartered in Miami, Florida. “

Imi Plc (OTCMKTS:IMIAY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $29.00 target price on the stock. According to Zacks, “IMI PLC is an engineering company. It provides designs, manufactures and services for engineered products which control the movement of fluids. The company primarily serves energy, transportation and infrastructure sector. IMI PLC is headquartered in Birmingham, the United Kingdom. “

Adesto Technologies Corporation (NASDAQ:IOTS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $9.00 target price on the stock. According to Zacks, “Adesto Technologies Corporation is a provider of application-specific non-volatile memory products. The company designed and built a portfolio of innovative products which includes Fusion Serial Flash, DataFlash(R) and Conductive Bridging RAM (R). It sells products directly to original equipment manufacturers and original design manufacturers. Adesto Technologies Corporation is headquartered in Sunnyvale, California. “

Infinity Property and Casualty Corporation (NASDAQ:IPCC) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. Zacks Investment Research currently has $122.00 price target on the stock. According to Zacks, “Infinity Property is a property and casualty insurer. “

Ideal Power (NASDAQ:IPWR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $1.75 target price on the stock. According to Zacks, “Ideal Power, Inc. is engaged in development of a novel, patented power conversion technology called Power Packet Switching Architecture(TM). The company also provides photovoltaic inverters and battery converters for grid storage and electrified vehicle fast-charging infrastructure. In addition, it offers hybrid power conversion systems and power switches. Ideal Power, Inc. is based in Spicewood, Texas. “

Investors Real Estate Trust (NYSE:IRET) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $6.50 target price on the stock. According to Zacks, “Investors Real Estate Trust is a real estate investment trust operating in the Midwest. “

Jounce Therapeutics (NASDAQ:JNCE) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States. “

Key Energy Services (NYSE:KEG) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Key Energy Services, Inc. is an onshore, rig-based well servicing contractor. The company’s services include drilling and workover rigs, coiled tubing, frac stack and well testing, fluid services, onshore and deepwater fishing and rental services. It operates primarily in United States, Mexico, Colombia, Ecuador, the Middle East and Russia. Key Energy Services, Inc. is headquatered in Houston, Texas. “

KemPharm (NASDAQ:KMPH) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $4.25 price target on the stock. According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “

Receive News & Ratings for H Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply